$0.04
(Market cap
$85 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
60,825,844
5 Years Aggregate
CFO
$-32.26 Mln
EBITDA
$-37.50 Mln
Net Profit
$-62.03 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MAIA Biotechnology Inc (MAIA)
| -13.7 | -- | 3.1 | -12.0 | -10.6 | -- | -- |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
MAIA Biotechnology Inc (MAIA)
| -22.7 | 68.5 | -66.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MAIA Biotechnology Inc (MAIA)
|
1.3 | 84.6 | 0.0 | -26.9 | -- | -232.9 | -- | 4.1 |
| 86.0 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 73.5 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 368.2 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.0 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout MAIA Biotechnology Inc (MAIA)
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical... development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Read more
-
Co-Founder, President, CEO & Chairman of the Board of Directors
Dr. Vlad Vitoc M.B.A., M.D.
-
Co-Founder, President, CEO & Chairman of the Board of Directors
Dr. Vlad Vitoc M.B.A., M.D.
-
Headquarters
Chicago, IL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for MAIA Biotechnology Inc (MAIA)
What is the current share price of MAIA Biotechnology Inc (MAIA) Today?
The share price of MAIA Biotechnology Inc (MAIA) is $1.32 (NYSE) as of 03-Sep-2026 15:44 EDT. MAIA Biotechnology Inc (MAIA) has given a return of -10.64% in the last 3 years.
What is the current PB & PE ratio of MAIA Biotechnology Inc (MAIA)?
Since, TTM earnings of MAIA Biotechnology Inc (MAIA) is negative, P/E ratio is not available.
The P/B ratio of MAIA Biotechnology Inc (MAIA) is 4.06 times as on 21-Aug-2026, a 22 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.19 |
20.68 |
2024 |
-2.23 |
14.25 |
2023 |
-1.01 |
41.62 |
2022 |
-2.06 |
3.83 |
2021 |
-- |
-- |
What is the 52 Week High and Low of MAIA Biotechnology Inc (MAIA)?
The 52-week high and low of MAIA Biotechnology Inc (MAIA) are Rs 3.19 and Rs 0.87 as of 04-Sep-2026.
What is the market cap of MAIA Biotechnology Inc (MAIA)?
MAIA Biotechnology Inc (MAIA) has a market capitalisation of $ 85 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in MAIA Biotechnology Inc (MAIA)?
Before investing in MAIA Biotechnology Inc (MAIA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.